Effects of electrostimulation in patients with chronic pain from HIV

Inclusion criteria: Women with HIV/AIDS; aged between 18 and 65 years; in antiretroviral therapy; have neuropathic cervicalgia, confirmed by LANSS scale. Exclusion criteria: Active contagious infection (meningitis, pulmonary tuberculosis); history of chronic diseases associated with neuropathic pain (diabetes, lupus, rheumatoid arthritis, infection by Human T‐cell Lymphotropic Virus); chronic renal or peripheral vascular insufficiency; oncologic disease; severe disease that limits the understanding of the informed consent or tests HIV Neuropathy Other hereditary and idiopathic neuropathies ;A00‐B99;Other hereditary and idiopathic neuropathies Interferential Current (IFC) (n=18) regulated in a 4000 Hz, modulated at 100 Hz (AMF), ranging 50 Hz (?F AMF) to not cause stimuli accommodation, with a delivery ramp of 1:5:1 (SLOPE). IFC was applied in a tetrapolar mode at the cervical region with therapy time of 15 minutes Interferential Current (IFC) Sham (n=18) patients receive normal dose, according to their current perception, and after 30 seconds the current has its dose reset gradually in 15 seconds, totalizing 45 seconds, and so it remains until the end of therapy;Device;Electric Stimulation Therapy Pain Pressure Threshold improvement, verified with an electronic pressure algometer (Somedic AB, Stockholm, Sweden), used to determine maximum tolerable pressure on the cervical surface (local effect), in the forearm and anterior tibial muscle (peripheral effect), through an improvement of a P<0.05;Outcome found: P smaller than 0.05 in active group in cervical surface, forearm and anterior tibial muscle. No False